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A 36-year-old Chinese man presented to the Queen Mary Hospital in August
1999 with a 2-week history of jaundice due to propylthiouracil treatment
for thyrotoxicosis. He had previously received carbimazole but had developed
an urticarial skin rash after 2 weeks of treatment. The patient developed
liver failure and fulminant pneumonitis shortly after hospital admission.
Despite receiving treatment with broad-spectrum antibiotics and intravenous
immunoglobulin, he died 11 days after the onset of the respiratory symptoms.
Postmortem examination using electron microscopy showed typical glycogen
bodies within the cytoplasm of the hepatocytes, which corresponded to
eosinophilic cytoplasmic inclusion bodies visible under light microscopy.
Immunohistochemical studies of the inclusion bodies were positive for
carcinoembryonic antigen and albumin, and negative for fibrinogen,
complement protein C3, immunoglobulins G, M, and A, α-fetoprotein, and
α-1-antitrypsin. This is the first report of a patient who received two
sequential antithyroid drugs and developed predominate cholestasis with
unique histological features. Extreme caution should be taken when a patient
develops allergy to one type of antithyroid drug, because cross-reactivity
may develop to the other type.
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Introduction
Cholestatic jaundice is a rare but potentially fatal complication arising from the
use of the antithyroid drugs carbimazole and propylthiouracil. The underlying
mechanism of pathogenesis is still unclear, and no known effective medical
therapy has been found. We report on a man who developed cholestatic jaundice
shortly after receiving sequential carbimazole and propylthiouracil treatment for
thyrotoxicosis.
Case report
A 36-year-old Chinese man who had neglected symptoms of thyrotoxicosis for 1
year was treated by his family physician with carbimazole 10 mg three times
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daily. An urticarial skin rash developed after 2 weeks of
treatment, which was thus switched to propylthiouracil
100 mg three times daily. The patient developed jaundice 2
weeks later and was referred to the Queen Mary Hospital in
August 1999.
The patient gave no history of hepatitis, alcohol, or drug
abuse. Physical examination detected jaundice and multiple
shotty cervical lymphadenopathy. The liver was enlarged
to 3 cm below the costal margin, but it was soft and smooth.
There was no skin rash or any sign of chronic liver disease.
The liver biochemistry tests showed an elevated serum
concentrations of bilirubin 214 µmol/L (reference range,
5-21 µmol/L), alkaline phosphatase 529 U/L (50-120 U/L),
γ-glutamyltransferase 321 U/L (0-30 U/L), alanine
aminotransferase 124 U/L (10-40 U/L), and aspartate
aminotransferase 85 U/L (20-48 U/L). A low white blood
cell count of 2.9 x 109 /L (reference range, 4.5-11.0 x 109 /L)
was noted on admission but the count quickly returned to
normal 10 days later. There was no eosinophilia, and the
clotting profile was normal. The level of free thyroxine was
51 pmol/L (reference range, 12-30 pmol/L) and the level of
thyrotropin (thyroid-stimulating hormone) was less than
0.03 mIU/L (0.5-5.0 mIU/L). The tests for antibodies
against hepatitis A, B, and C viruses all gave negative results.
Furthermore, antibodies against cytomegalovirus, herpes
simplex virus, and Epstein-Barr virus were also absent. The
anti-mitochondrial antibody and anti-smooth muscle
antibody test results were negative as well.
An ultrasonography scan of the liver showed no stone in
the gall bladder and common bile duct, although the
intrahepatic ducts were prominent at the left lobe. Because
cholangitis could not be excluded, an endoscopic retrograde
cholangiopancreatography was performed, but the biliary
tree was found to be normal. A percutaneous liver biopsy
was thus performed.
The patient’s liver biochemistry test results progressively
worsened after admission. A course of oral prednisolone at
0.5 mg/kg was started with the presumptive diagnosis of
drug-induced cholestasis. Subsequently, the serum alkaline
phosphatase concentration decreased from 657 U/L to
194 U/L, but the bilirubin concentration continued to rise
and peaked at 862 µmol/L 12 days after starting therapy
(Fig 1). The prothrombin time remained unchanged.
Prednisolone administration was continued for 10 days and
then gradually tapered off.
The patient developed a swinging fever 10 days after
stopping steroid treatment and was asymptomatic, with no
chest symptoms and no sputum production. Chest X-rays,
ultrasonography of the liver, and echocardiography did not
reveal an infective focus. However, the patient developed
shortness of breath with greenish sputum 6 days later. The
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Fig 1. Time course of the change in liver biochemistry during steroid treatment
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chest X-ray showed bilateral diffused haziness with ill-
defined air-space shadows in both lungs, suggesting
fulminant pneumonitis. Yet, repeated sputum, blood, and
broncho-alveolar lavage were all negative for known
organisms.
Results from an open lung biopsy revealed no granu-
lomatous inflammation, and staining for acid-fast bacilli
and fungi was negative. Immunostaining for herpes simplex
virus and cytomegalovirus was also negative. The overall
picture was compatible with acute lung injury, with diffused
alveolar injury, acute interstitial pneumonia, or pneumonitis.
Despite treatment with broad-spectrum antibiotics and intra-
venous immunoglobulin, the patient died 11 days after the
onset of the respiratory symptoms.
The liver tissue showed preserved acinar architecture.
There was prominent intracanulicular cholestasis in
acinar zones 2 and 3. Inflammation was minimal and
apoptotic bodies were not visible. Fatty change was absent.
In addition, microscopy revealed numerous cytoplasmic,
weakly eosinophilic inclusion bodies, which were variable
in size, positive for periodic acid-Schiff, and sensitive to
diastase digestion.
Immunohistochemical studies showed that the inclusion
bodies were positive for carcinoembryonic antigen and
albumin, and negative for fibrinogen, complement protein
C3, immunoglobulins G, M, and A, α-fetoprotein, and α-1-
antitrypsin. Immunostaining for herpes virus antigens
HBsAg and HBcAg were negative. The portal tracts were
mildly expanded by moderate lymphocytic infiltration with
a small number of neutrophils but no eosinophils.
Electron microscopic examination of liver tissue revealed
typical glycogen bodies within the cytoplasm of the
hepatocytes, which corresponded to the eosinophilic
cytoplasmic inclusion bodies that were visible under light
microscopy (Fig 2a). The glycogen bodies had concentric
arrays of smooth membranes associated with glycogen
rosettes (Fig 2b).
Discussion
The patient in this case fulfilled the diagnostic criteria of
drug-induced hepatotoxicity as proposed by Hanson in
19841: the absence of serological evidence of viral hepatitis
infection, absence of chronic liver disease, and absence of
drug or alcohol misuse with a temporal relation to drug
therapy. The persistent ultrasound findings could be
attributed to the marked cholestasis.
Antithyroid drugs have been reported to induce liver
toxicity but usually in the form of acute hepatitis with
elevation of parenchymal enzymes.1,2 The occurrence of
acute cholestasis is rare, although it is associated more
commonly with carbimazole than with propylthiouracil.
Hepatotoxicity, mainly in the form of cholestasis, has been
reported in six cases of carbimazole use3-7 and in one of
propylthiouracil use.8 Only one study reported that cross-
reactivity of the two drugs caused hepatotoxicity.7
Either carbimazole or propylthiouracil may have been
the cause of the hepatotoxicity in the patient in this case.
Cholestasis usually develops around several weeks after
carbimazole use, but it may take only 1 day after propyl-
thiouracil use.9 However, the possibility of crossover
reactivity between the two drugs cannot be excluded.
Cross-sensitivity has been reported to occur in about
50% of patients in one study.10  The levels of bilirubin and
alkaline phosphatase in the patient in our case were twice as
high as those reported. We thus suspect cross-reactivity of
the two drugs occurred.
The successful use of steroid has been reported for
fulminant hepatitis caused by antithyroid agents.11,12 The
underlying mechanism of the hepatotoxicity may be
immune-mediated, as evidenced by the observation that
toxic symptoms occurred at an accelerated rate on
rechallenge with antithyroid drugs.13 In addition, peripheral
lymphocyte sensitisation to propylthiouracil has been
demonstrated in vitro.14,15 However, the type of hepatic
injury was hepatocellular in those steroid-responsive cases.
Fig 2. (a) Photomicrograph showing weakly eosinophilic cytoplasmic inclusion bodies (arrows) in the hepatocytes (H&E, x600);
(b) electron micrograph showing glycogen bodies with semiconcentric or concentric arrays of smooth membranes associated
with glycogen rosettes (x 13 350)
(a) (b)
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The use of steroid has not been reported before in patients
with cholestatic hepatotoxicity.
The type of liver injury in patients receiving propyl-
thiouracil and carbimazole reported previously was usually
hepatitic or mixed cholestatic hepatitis. Liver biopsy often
revealed portal inflammatory changes and hepatocyte
necrosis, with or without intracanalicular cholestasis. Cho-
lestasis with minimal inflammation and absent apoptotic
bodies has not been reported previously, and this is also
the first reported case demonstrating numerous glycogen
inclusion bodies in the liver biopsy specimen from a patient
receiving antithyroidal drugs.
Glycogen inclusion bodies in drug-induced hepatotox-
icity have been reported in patients taking anabolic steroids,
trimethoprim or sulfamethoxazole, 6-mercaptopurine,
methotrexate, nitrofurantoin, or vitamin A.16 Whether
carbimazole or propylthiouracil is the cause of the increase
in glycogen inclusion bodies cannot be ascertained. The
reported features of liver biopsies in patients with hepa-
totoxicities because of carbimazole and propylthiouracil
are summarised in the Table.
The cause of the lung injury in this patient could be
ascertained. We postulate that it was due to superimposed
opportunistic infection during steroid treatment, or due to a
generalised immune-mediated reaction involving the liver,
as well as the lung. Hence, extreme caution should be taken
when a patient develops hepatotoxicity in response to one
type of antithyroidal agent, because cross-reactivity may
develop in response to a second type of antithyroidal drug.
The use of steroid in this condition is still uncertain. Further
studies are needed on the mechanisms of antithyroid drugs
causing hepatotoxicity and on the use of steroid in these
conditions.
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Table. Summary of histological findings in published adult cases of carbimazole- and propylthiouracil-induced cholestasis
since 1980
